by April Breyer Menon | Oct 16, 2019
In an article for Bloomberg Law, Venable partner Ha Kung Wong discusses how the U.S. patent system and inter partes review (IPR) proceedings affect pharmaceutical innovation. The article can be viewed here.
by April Breyer Menon | Oct 8, 2019
Download PDF Download...
by April Breyer Menon | Oct 1, 2019
In an article for MedCity News, Venable partner Ha Kung Wong discusses reasons for the slow uptake of biosimilars in the US. The article can be viewed here.
by April Breyer Menon | Sep 30, 2019
Biosimilar uptake has been low in the United States so far, with market shares for most biosimilars under 10%. Given the cost savings potential, trying to increase biosimilar uptake has been high on Congress’ agenda. There are many bills pending in Congress dealing...
by April Breyer Menon | Sep 9, 2019
Download PDF Download...